Bristol-Myers Squibb: drug combination fails cancer study
(CercleFinance.com) - Cancer treatment Opdivo plus Yervoy - a key asset of Bristol-Myers Squibb - has failed as a maintenance therapy in a late-stage study on patients with small cell lung cancer after completion of first-line chemotherapy, the US drugmaker said on Tuesday.
This morning Bristol-Myers Squibb announced that a Phase 3 study did not meet its primary endpoint of overall survival (OS) with Opdivo in combination with Yervoy, versus placebo, as a maintenance therapy for patients with extensive-stage small cell lung cancer (SCLC) without disease progression after completion of first-line platinum-based chemotherapy.
The biopharmaceutical company's shares are down over 3% in pre-market trading.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This morning Bristol-Myers Squibb announced that a Phase 3 study did not meet its primary endpoint of overall survival (OS) with Opdivo in combination with Yervoy, versus placebo, as a maintenance therapy for patients with extensive-stage small cell lung cancer (SCLC) without disease progression after completion of first-line platinum-based chemotherapy.
The biopharmaceutical company's shares are down over 3% in pre-market trading.
Copyright (c) 2018 CercleFinance.com. All rights reserved.